Septerna

Historical price data

Septerna's mission is to unlock the vast therapeutic potential of G protein-coupled receptors (GPCRs), a historically productive but still largely underexploited target class. The company has achieved rapid progress, advancing its wholly-owned lead programs into Phase 2 and Phase 1 clinical trials, powered by its industrial-scale Native Complex Platform®. Its strategy combines internal development of high-value, biomarker-driven programs with selective partnerships for complex indications, aiming to deliver a portfolio of novel, oral, disease-modifying medicines.

The Native Complex Platform® is an industrial-scale technology that reconstitutes GPCRs with their native ligands, transducer proteins, and lipids to enable high-resolution structural analysis and screening for novel small molecule drug discovery.